Brca1 Brca2
Brca1 Brca2 - Related Videos
08:15
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
0 Views •
2014
gDNA enrichment for NGS sequencing is an easy and powerful tool for the study of constitutional mutations. In this article, we present the procedure to analyse simply the complete sequence of 11 genes involved in DNA damage repair.
09:24
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
0 Views •
Cited by 1 •
2015
Gene silencing by siRNA represents a convenient experimental strategy to analyze BRCA2-dependent biological functions with immediate implications to better understand cancer biology. A method to efficiently silence BRCA2, along with the experimental procedure to detect and quantify changes in BRCA2 protein expression by immunoblotting in human cell lines, is presented.
08:53
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
0 Views •
Cited by 15 •
2011
We provide a method for testing BRCA1 variants in a tissue culture based assay for homologous recombination repair of DNA damage by depleting endogenous BRCA1 protein from a cell using RNAi and replacing it with a BRCA1 point mutant that contains a coding change.
09:22
Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
0 Views •
Cited by 1 •
2021
People with BRCA1 mutations have a higher risk of developing cancer, which warrants accurate evaluation of the function of BRCA1 variants. Herein, we described a protocol for functional assessment of BRCA1 variants using CRISPR-mediated cytosine base editors that enable targeted C:G to T:A conversion in living cells.
02:58
CRISPR-Mediated Base Editing Tools: A Genome Editing Technique to Induce Targeted Base Substitution
0 Views •
2025
This video explains the concept of CRISPR-mediated cytosine base editors for inducing targeted nucleotide substitution.
FAQs
The key consequence is reduced ability to repair DNA double-strand breaks through homologous recombination, a high-fidelity repair pathway. When this process is impaired, cells are less effective at preserving genome stability after damaging events. This connection explains why BRCA1 and BRCA2 variants are important in cancer biology and why researchers study their effects on DNA-repair weaknesses.
Homologous recombination provides a high-fidelity route for repairing DNA double-strand breaks, so its activity is central to maintaining genome stability. Studying BRCA1 and BRCA2 in this pathway helps researchers connect molecular defects with disease risk. It also provides a biological basis for investigating treatments designed to exploit weaknesses in DNA repair rather than treating all tumors identically.
Inherited variants are present as part of a person’s genetic background, whereas acquired variants arise during a person’s lifetime. Both types can impair the functions associated with BRCA1 or BRCA2 and contribute to cancer risk, but distinguishing them supports different research questions. This distinction is especially relevant to hereditary disease studies and genetic risk assessment.
PARP inhibition is studied as a targeted strategy for cancers with weaknesses in DNA repair involving BRCA1 or BRCA2. Rather than addressing every cancer through the same treatment approach, this strategy uses a tumor’s repair vulnerability as a therapeutic feature. The relationship illustrates how knowledge of DNA-repair defects can guide precision medicine and treatment development.
Assessment of BRCA1 and BRCA2 variants can help evaluate inherited susceptibility to cancers associated with these genes, including breast, ovarian, prostate, and pancreatic cancer. The findings contribute to understanding hereditary disease and can support research into how genetic information relates to cancer risk. They also provide an important foundation for precision-medicine approaches.
BRCA1 and BRCA2 connect a defined genetic feature with a recognizable DNA-repair weakness and a set of associated cancer risks. That relationship allows researchers to link genetic information, cancer biology, and targeted treatment development. Their study demonstrates how understanding the molecular basis of hereditary disease can help identify therapies tailored to particular biological vulnerabilities.